Delivery Order SPE2DB20D1100-SPE2DB25FD9P9
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,855.20 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets (30-count units). This firm fixed-price delivery order, issued on July 29, 2025, with an ultimate completion date of August 19, 2025, represents a non-competitive, non-set-aside award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under the company's...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.52 for ORGOVYX 120 mg tablets (30-count units) on July 24, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. ORGOVYX is a prescription medication used in the treatment of prostate cancer, reflecting DLA's ongoing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of ORGOVYX 120 mg tablets in packages of 30 units. This is a firm fixed-price delivery order with a ceiling value of $1,385.52, with an ultimate completion date of August 19, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units, with a contract ceiling value of $1,385.52. This firm fixed-price delivery order represents a non-set-aside competitive award with an ultimate completion date of August 20, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. ORGOVYX...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count unit dose) valued at $1,385.52 with a firm fixed price arrangement. This non-competitive, non-set-aside delivery order was awarded on August 8, 2025, with an ultimate completion date of August 29, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $5,542.08 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets (30-count units) on July 31, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award to the prime contractor and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. ORGOVYX is a prescription medication used in the treatment...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count unit of use packaging) valued at $1,385.52, with an ultimate completion date of August 14, 2025. This non-set-aside contract utilizes firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement running through December...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 MG tablets, quantity 30s, with a ceiling value of $4,156.56. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of August 21, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. ORGOVYX is a prescription medication used in the...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the prescription medication Orgovyx (relugolix) 120 mg tablets. The contract has a ceiling value of $4,156.56 and a period of performance through May 14, 2025. The contract is a firm fixed-price delivery order and does not have a set-aside designation, indicating open competition. AmerisourceBergen, as the prime contractor, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units, with a ceiling value of $1,385.52 and a firm fixed price contract type. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award carries no set-aside designation,...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD9P9Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for supply of ORGOVYX (relugolix) 120 mg tablets in a quantity of 30 units under a firm fixed-price contract. The award, issued on August 8, 2025, carries a ceiling value of $1,385.52 and requires ultimate completion by August 29, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. The contract will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. ORGOVYX, a prostate cancer treatment, represents one of the specialized medications within the company's extensive portfolio of federal medical deliveries, which encompass specialty medications, brand-name and generic drugs, vaccines, and related healthcare commodities across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/8/25 |